Variable (LO/HI)
|
Anti-PD-1 PFS
|
---|
Univariable analysis
|
Multivariablea analysis per variable
|
Multivariablea analysis with Thy1, SMA, FAP
|
---|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
---|
Thy1+/total
|
2.18 (1.17–3.81)
|
0.016
|
2.34 (1.21–4.28)
|
0.013
|
1.90 (0.98–3.48)
|
0.058
|
SMA+/Thy1+
|
0.55 (0.32–0.97)
|
0.038
|
0.55 (0.32–0.99)
|
0.048
|
0.71 (0.40–1.31)
|
0.26
|
FAP+/Thy1+
|
1.77 (1.11–2.89)
|
0.017
|
2.08 (1.28–3.44)
|
0.0030
|
1.79 (1.06–3.04)
|
0.031
|
- Abbreviations: CAF cancer-associated fibroblast, CI confidence interval, HI high, HR hazard ratio, LO low, PFS progression-free survival
- aCox proportional hazards model included age, sex, mutation status, stage, treatment, and prior immune checkpoint blockade as covariates